OBJECTIVE: The aim of this study was to evaluate the efficacy of adding bevacizumab to @entity1311 and @entity3003 and as maintenance in a larger cohort of @entity1 with advanced or recurrent @entity1204 . METHODS: We retrospectively identified @entity1204 @entity1 treated with @entity1311 (175 mg/m per 3 hours), @entity3003 (area under the curve, 5) and bevacizumab (15 mg/kg) and maintenance bevacizumab treated in a post-protocol treatment cohort and evaluated them with our previously published phase 2 trial of this regimen. RESULTS: Twenty-seven additional @entity1 were identified; 19 received the regimen as first-line therapy, and 8 received the regimen as second-line therapy after prior @entity1311 and @entity3003 . The 19 @entity1 who received first-line therapy were analyzed alone and with the 15 @entity1 enrolled on protocol. The 2 cohorts were similar with respect to risk factors. Overall survival curves were not statistically different between the protocol and the postprotocol @entity1 (log-rank test; P > 0.1). Collectively, a total of 266 courses (median, 6 courses; range, 1-20 courses) of @entity3003 , @entity1311 , and bevacizumab combination therapy and 305 courses (median, 16 courses; range, 0-45courses) of bevacizumab maintenance therapy were administered as first-line therapy. Collectively, the median progression-free survival was 20 months, and median overall survival was 56 months. Among 29 @entity1 with measurable disease, the response rate was 82.8% (95% confidence interval, 69.0%-96.5%; 15 complete responses and 9 partial responses). Among the 8 @entity1 who received @entity1311 and @entity3003 and bevacizumab as second-line therapy after @entity1311 and @entity3003 , the response rate was 87.5% (6 complete responses, 1 partial response). Their median progression-free survival and median overall survival were not reached after a median follow-up of 23.5 months. CONCLUSIONS: Although there are inherent limitations to small retrospective studies, this second analysis confirms the high response rate, progression-free survival, and overall survival in the bevacizumab, @entity1311 , and @entity3003 regimen as first-line therapy in advanced and recurrent @entity1204 .

@entity1311 , @entity3003 , and Bevacizumab in Advanced and Recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'endometrial cancer']
@entity1204 :: (MESH:D016889,Disease) :: ['Endometrial Carcinoma']
